» Articles » PMID: 17005715

Limitations of the New York Heart Association Functional Classification System and Self-reported Walking Distances in Chronic Heart Failure

Overview
Journal Heart
Date 2006 Sep 29
PMID 17005715
Citations 155
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Two ways to evaluate the symptoms of heart failure are the New York Heart Association (NYHA) classification and asking patients how far they can walk (walk distance). The NYHA system is commonly used, although it is not clear how individual clinicians apply it.

Aim: To investigate how useful these measures are to assess heart failure and whether other questions might be more helpful.

Methods: 30 cardiologists were asked what questions they used when assessing patients with heart failure. To assess interoperator variability, two cardiologists assessed a series of 50 patients in classes II and III using the NYHA classification. 45 patients who had undergone cardiopulmonary testing were interviewed using a specially formulated questionnaire. They were also asked how far they could walk before being stopped by symptoms, and then tested on their ability to estimate distance.

Results: The survey of cardiologists showed no consistent method for assessing NYHA class and a literature survey showed that 99% of research papers do not reference or describe their methods for assigning NYHA classes. The interoperator variability study showed only 54% concordance between the two cardiologists. 70% of cardiologists asked patients for their walk distance; however, this walk distance correlated poorly with actual exercise capacity measured by cardiopulmonary testing (rho = 0.04, p = 0.82).

Conclusion: No consistent method of assessing NYHA class is in use and the interoperator study on class II and class III patients gave a result little better than chance. Some potential questions are offered for use in assessment. Walking distance, although frequently asked, does not correlate with formally measured exercise capacity, even after correction for patient perception of distance, and has never been found to have prognostic relevance. Its value is therefore doubtful.

Citing Articles

Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF.

McDowell K, Docherty K, Campbell R, Henderson A, Jhund P, Claggett B JAMA Cardiol. 2025; .

PMID: 40042880 PMC: 11883611. DOI: 10.1001/jamacardio.2025.0025.


The simpler modified fried frailty scale predicts 2-year mortality in older adults with heart failure: a pilot study.

Kucuk C, Ozkok S, Bahat G, Karaayvaz E, Altinkaynak M, Medetalibeyoglu A BMC Geriatr. 2025; 25(1):50.

PMID: 39844032 PMC: 11753092. DOI: 10.1186/s12877-025-05698-y.


Natural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure.

Adejumo P, Thangaraj P, Dhingra L, Aminorroaya A, Zhou X, Brandt C JAMA Netw Open. 2024; 7(11):e2443925.

PMID: 39509128 PMC: 11544492. DOI: 10.1001/jamanetworkopen.2024.43925.


Sex Differences in the Relationship between New York Heart Association Functional Classification and Survival in Cardiovascular Disease Patients: A Mediation Analysis of Exercise Capacity with Regular Care Data.

Siegersma K, Stens N, Groepenhoff F, Appelman Y, Tulevski I, Hofstra L Rev Cardiovasc Med. 2024; 23(8):278.

PMID: 39076639 PMC: 11266952. DOI: 10.31083/j.rcm2308278.


Bioimpedance analysis predicts worsening events in outpatients with heart failure and reduced ejection fraction.

Rodriguez-Lopez C, German J, Venegas Rodriguez A, Carda Barrio R, Gaebelt Slocker H, Lazaro A ESC Heart Fail. 2024; 11(6):3892-3900.

PMID: 39044354 PMC: 11631312. DOI: 10.1002/ehf2.14908.


References
1.
Cohn J, Anand I, Latini R, Masson S, Chiang Y, Glazer R . Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation. 2003; 108(11):1306-9. DOI: 10.1161/01.CIR.0000091234.45664.62. View

2.
Bohm M, Maack C, Wehrlen-Grandjean M, Erdmann E . Effect of bisoprolol on perioperative complications in chronic heart failure after surgery (Cardiac Insufficiency Bisoprolol Study II (CIBIS II)). Z Kardiol. 2003; 92(8):668-76. DOI: 10.1007/s00392-003-0959-7. View

3.
Abdulla J, Burchardt H, Abildstrom S, Kober L, Torp-Pedersen C . The angiotensin converting enzyme inhibitor trandolapril has neutral effect on exercise tolerance or functional class in patients with myocardial infarction and reduced left ventricular systolic function. Eur Heart J. 2003; 24(23):2116-22. DOI: 10.1016/j.ehj.2003.09.004. View

4.
Adamopoulos S, Parissis J, Paraskevaidis I, Karatzas D, Livanis E, Georgiadis M . Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 2003; 24(24):2186-96. DOI: 10.1016/s0195-668x(03)00480-9. View

5.
Muller K, Gamba G, Jaquet F, Hess B . Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life. Eur J Heart Fail. 2003; 5(6):793-801. DOI: 10.1016/s1388-9842(03)00150-8. View